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Background: The authors herein report a case of pain, femoral vein thrombosis, and inguinal subcutaneous
hematoma caused by percutaneous femoral vascular catheterization in a hemodialysis (HD) patient complicated
with vascular access occlusion. The pain was well-controlled without using analgesics such as non-steroidal anti-
inflammatory drugs (NSAIDs). The thrombosis and hematoma increased in size and was also treated by conservative
treatment using traditional Japanese Kampo medicine (jidabokuippo: JDI) to resolve oketsu: a sign of microcirculating
disorder. JDI improves the blood circulation in the affected lesion and alleviates contusion-induced blood flow and
repairs blood flow without forming thrombosis. These catheter-related complications were successfully treated by JDI.
Case presentation: A 41-year-old man under HD was admitted because of permanent vascular access failure. He had
a history of side effects of gastrointestinal bleeding associated with use of NSAIDs and accompanied with femoral vein
thrombosis and inguinal subcutaneous hematoma caused by percutaneous femoral vascular catheterization.
The hematoma increased in size and was treated using JDI. In the present case, pain, venous thrombosis, and
subcutaneous hematoma surprisingly improved with use of JDI in addition to combination therapy with
anticoagulant (warfarin potassium) and antibiotic (meropenem hydrate), without using analgesics such as NSAIDs.
Conclusions: The present case indicated as follows: JDI controls the pain associated with hematoma without
analgesics such as NSAIDs; JDI also has an effect of improving the complications associated with venous
thrombosis and subcutaneous hematoma caused by catheterization in HD patients safely. JDI, one of Kampo
drugs, has few side effects and can be used as needed.
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Percutaneous femoral catheterization is considered a quick
and an easy access for emergency case under hemodialysis
(HD) patient complicated with vascular access occlusion.
However, it may cause severe and fatal complications such
as infection, hematoma, deep vein thrombosis, and vessel
perforation [1].
Conservative treatment of hematoma is acceptable if no
hemodynamic dysfunction is present; no compartment
syndrome is present; pain control is well-managed by
analgesic drugs such as non-steroidal anti-inflammatory
drugs (NSAIDs); and the hematoma does not increase in
size.
The authors herein report a case of pain, femoral vein
thrombosis, and inguinal subcutaneous hematoma caused
by percutaneous femoral vascular catheterization. The
thrombosis and hematoma increased in size and was
successfully treated by conservative treatment using
traditional Japanese Kampo medicine (jidabokuippo: JDI)
to resolve oketsu: a sign of microcirculating disorder. The
pain was also well-controlled without using analgesics. To
our knowledge, no reports are available concerning the
effectiveness of JDI for catheter-related complications in
patients under HD.Case presentation
A 41-year-old man (Japanese) under HD attributable to
lupus nephritis for approximately 16 years with a his-
tory of vascular access trouble several times was admit-
ted to our hospital because of permanent vascular
access failure (day 1). Ultrasonography revealed that
thrombosis obstructed the vascular access almost com-
pletely from the anastomosis of the brachial artery and
artificial vessel toward the anastomosis of the brachial
vein and artificial vessel. He had a risk factor of throm-
bosis with history of systemic lupus erythematosus (SLE)
for 20 years. However, the laboratory data findings showedFig. 1 A contrast-enhanced computed tomography scan revealed (left pan
hematoma inside the sartorius muscle and rectus femoris muscle (arrow) (dthat anti-double strand DNA IgG antibody and anticardio-
lipine antibody remained negative, and 50% hemolytic unit
factor (CH50), C3, and C4 remained within normal range
for recent 15 years. Thrombocytopenia was not observed.
These data indicated that immunological activity of SLE
was in remission.
The authors concluded the patient had no indication
of thrombectomy nor percutaneous angioplasty. Percu-
taneous femoral vascular catheter was inserted (left)
under ultrasonography guidance using the Seldinger
technique because the patient had a history of carotid
vein damage and subclavian vein stenosis. Since main-
taining the appropriate blood flow rate was difficult, fem-
oral vascular catheter was inserted again in the opposite
(right) side. After the first HD session of catheterization,
he complained of pain in the left groin; a hard, smooth,
painful mass was palpable; and subcutaneous hemorrhage
was also observed. The left groin was compressed with an
elastic bandage.
On day 3, laboratory data findings showed elevation of
d-dimer level (13.2 μg/mL) without any abnormality in
blood coagulopathy, but no progression in the decrease
of hemoglobin level. The patient also showed shivering
and spiking fever (39 °C) and complained of continuous
pain in the groin; therefore, the catheter was immedi-
ately removed. Contrast-enhanced computed tomog-
raphy (CECT) revealed a thrombosis in the right side of
the external iliac vein (Fig. 1, left panel) and a soft-tissue
mass in the left side of the groin (Fig. 1, right panel), but
revealed no pulmonary embolism.
Warfarin potassium was administered to maintain pro-
thrombin time-international normalized ratio with the
range from 1.5 to 2.5 (2.0 mg/day). On the other hand,
blood culture test was positive (Staphylococcus aureus),
and laboratory data findings showed elevation of both
white blood cell count (12,400/μL) and C-reactive protein
(CRP) (8.6 mg/dL). Meropenem hydrate (0.5 g/day) was
also administered for infectious disease.el) venous thrombosis in the external iliac vein (arrow) and (right panel)
ay 3)
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to protect from new onset of pulmonary embolism at-
tributable to the findings as follows: ultrasonic echocar-
diography showed no abnormality, and the possibility
remained concerning risk of exacerbation of infections
by catheterization.
Based on these findings, the patient was diagnosed as
oketsu (blood stasis syndrome). Traditional Japanese
Kampo medicine, JDI (7.5 g/day: Tsumura, Tokyo, Japan),
was administered to improve the symptoms.
Visual analogue scale (VAS) scale in the groin reduced
from 85 (day 1) to 33 mm (day 7), thereafter, 12 mm (day
12). The subcutaneous hemorrhage disappeared com-
pletely on day 16. The firm mass in the left groin gradually
reduced in size and was not palpable on day 19.
Because laboratory data showed improvement in CRP
concentration of less than 0.01 mg/dL, blood culture test
remained negative, and clinical symptoms dramatically
improved, meropenem hydrate administration was termi-
nated on day 14. A d-dimer concentration also reduced
from 13.2 to 0.4 μg/mL on day 14. The patient underwent
successful arteriovenous graft formation in the right fore-
arm on day 15.
The CECT on day 21 revealed that venous thrombosis
in the right external iliac vein reduced (Fig. 2, left panel),
and hematoma inside the left sartorius muscle and rec-
tus femorius also reduced (Fig. 2, right panel); therefore,
the patient was discharged on day 22. The patient did
not use analgesic drugs such as NSAIDs throughout the
hospitalization.
JDI administration was terminated because no symp-
toms were observed on day 21. No adverse reactions to
the JDI treatment were observed.
Neither pulmonary embolism nor recurrence of ven-
ous thrombosis occurred until 6 months after discharge,
thereby, terminating warfarin potassium administration.Fig. 2 A contrast-enhanced computed tomography scan revealed that (left
with day 3 (arrow) and (right panel) hematoma inside the sartorius muscle
(day 21)At present, the patient is clinically well, showing no
signs of exacerbation or relapse of venous thrombosis
and subcutaneous hematoma.Discussion
The authors found out two important clinical issues in this
case. JDI controls the pain associated with subcutaneous
hematoma without using analgesics such as NSAIDs. JDI
also has an effect of improving the complications associ-
ated with venous thrombosis and subcutaneous hematoma
caused by percutaneous catheterization in HD patients.
First, the pain was well-controlled by conservative treat-
ment using traditional Japanese Kampo medicine JDI
without using analgesics. Several reports in the literature
describe the randomized controlled trial comparing the ef-
fects on rib fracture between JDI and NSAIDs showing
that the treatment period was shorter in JDI than NSAIDs;
thereby, JDI is an excellent analgesic from the viewpoint
of medical economics [2].
The prescription JDI has been developed by Shuan
Kagawa (herbalist), who lived in the eighteenth century,
Edo era, Japan [3]. JDI is an herbal mixture that im-
proves the blood circulation in the affected lesion and
alleviates contusion-induced swelling and pain. JDI also
has been reported to undo the stagnant blood flow and
repair blood flow without forming thrombosis. JDI is
composed of seven herbs as follows: cinamon bark,
cnidium rhizome, nuphar rhizome, quercus bark, glycyr-
rhiza root, rhubarb rhizome, and clove floral bud [4].
Cnidium rhizome exerts anti-inflammatory and analgesic
actions. Nuphar rhizome promotes the resorption of the
internal hemorrhage, thereby repairing damaged tissue.
Quercus bark has analgesic, anti-inflammatory, detoxyfy-
ing, and hemostatic properties. Rhubarb rhizome and
clove floral bud improve microcirculation [4]. Severalpanel) venous thrombosis in the external iliac vein reduced compared
and rectus femoris muscle also reduced compared with day 3 (arrow)
Wada et al. Renal Replacement Therapy  (2017) 3:3 Page 4 of 5reports in the literature describe that JDI includes herbs
with established antioxidant activity, which may act syn-
ergistically when administered as a combination [5–7].
Antioxidant activity has been reported to be involved in
the improvement of swelling and pain associated with
trauma [8]; therefore, JDI has mainly been used for
bruises and sprains in Japan [4]. Nevertheless, no reports
were available concerning the effectiveness of JDI in HD
patients. The current report indicates the possibility that
the pharmacological effect of JDI could be useful for HD
patients with catheter-related complications such as pain,
thrombosis, and hematoma. Moreover, in this case, JDI
was firstly administered as analgesic and was surprisingly
effective to resolve thrombosis and subcutaneous
hematoma, probably in part, attributable to the effect of
cnidium rhizome and quercus bark [4]. It still remains un-
clear whether JDI administration under the specific condi-
tion with renal dysfunction affected the improvement of
these catheter-related complications. However, treatment
by JDI should be considered as an option for catheter-
related complications among all patients with history of
side effects caused by NSAIDs.
In the pathological state, ketsu (blood and its metabolic
products that circulate throughout the body) manifests
stagnation known as oketsu according to the diagnostic
criteria [9]. The major formulations against oketsu for the
similar symptoms are as follows: (1) tsudosan, (2) tokaku-
jyokitou, (3) keishibukuryogan, and (4) JDI. To distinguish
JDI from other three formulations when prescribing, ab-
dominal symptoms type of sho based on Japanese Kampo
medicine show the characteristics as follows: (1) tsudosan,
complaint of having stuck sensations in the region be-
neath the heart; (2) tokakujyokitou, lower abdominal
strain appearing accompanied by severe sharp pain on
gentle rubbing by fingertip; and (3) keishibukuryogan, pain
at side of navel on palpitation. The pain produced at either
side of the navel on palpitation is an important abdominal
symptom of ketsu congestion. Ketsu-improving agent such
as keishibukuryogan may clear up this condition. The
present case did not show such abdominal symptoms. No
specific abdominal symptoms (type of sho by Kampo diag-
nosis) exist in the use of JDI [4]; therefore, JDI has been
widely used and classified as one of the major drugs im-
proving the pathological state called oketsu in Japanese
Kampo medicine.
According to the theory of Japanese Kampo medicine,
venous thrombosis and subcutaneous hematoma caused
by catheterization are considered as an oketsu condition: a
sign of microcirculating disorder. In the present case, pain,
thrombosis, and subcutaneous hematoma surprisingly im-
proved with use of JDI in addition to combination therapy
with anticoagulant and antibiotic. This could be attribut-
able to that oketsu condition was improved by JDI. The
result that the patient had no complication such asthrombosis or coagulation inside the HD circuit also
indicates that JDI unlikely inhibits the action of war-
farin and heparin. For the treatment of more severe
pain, thrombosis, and hematoma by catheterization, it
remains unclear which is better either JDI alone ther-
apy or combination therapy with other Kampo oketsu-
improving agents such as tsudosan, tokakujyokitou,
and keishibukuryogan in addition to JDI. This issue re-
mains to be solved in the future.
Second, femoral vein thrombosis and inguinal hematoma
were caused by percutaneous femoral catheterization. The
hematoma increased in size and was successfully treated
by conservative treatment using traditional Japanese
Kampo medicine JDI to resolve oketsu. The venous throm-
bosis decreased in size after combination therapy with JDI
and warfarin potassium.
Because anticoagulants such as heparin are regularly
administered in HD treatment, HD patients frequently
have complications associated with bleeding. The
present case also had a history of side-effects of gastro-
intestinal bleeding associated with use of NSAIDs, there-
fore, he was administered JDI. JDI can thus be used
safely and economically in HD patients with history of
gastrointestinal bleeding caused by NSAIDs.
According to the clinical guidance for the evaluation
and the treatment of cardiovascular complications in
HD patients by Japanese Society for Dialysis Therapy
[10], they state that warfarin potassium for HD patients
should be strictly monitored attributable to high risk of
bleeding complications such as cerebral hemorrhage in
the population [11, 12]. Warfarin potassium significantly
increases the risk for bleeding as creatinine clearance.
Non-vitamin K-dependent oral anticoagulant agents
(NOACs) are currently recommended for patients with
atrial fibrillation at risk for stroke instead of warfarin po-
tassium, however, all NOACs are dependent on kidney
function for elimination therefore contraindicated in HD
population [13]. Anticoagulant therapy for HD patients
is difficult accordingly.
If the patient was administered only warfarin potassium
as an anticoagulant therapy and meropenem hydrate with-
out JDI, the possibility remains that the pain control might
be more difficult, and it might take longer to diminish
venous thrombosis and hematoma. Therefore, the quality
of life of the patient might be reduced attributable to ex-
tension of hospitalization or medication period.
Because JDI contains rhubarb rhizome (laxative) [4], the
associated side effects of digestive symptoms such as epi-
gastralgia and diarrhea could be caused. In the present
case, the patient did not complain of such symptoms.
While taking JDI, the frequency of his bowel movements
improved regularly approximately once daily. HD patients
overall require water restriction, thereby complicating
constipation frequently. Laxative effect of rhubarb rhizome
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patients.
The favorable indication of JDI in HD patients could
be characterized as follows: (1) pain with history of
NSAIDs-related gastrointestinal bleeding, (2) complica-
tions associated with venous thrombosis or subcutane-
ous hematoma caused by catheterization, and (3) under
treatment with anticoagulants (bleeding tendency). On
the other hand, unfavorable indication of JDI in HD pa-
tients could be characterized as follows: patients who
cannot follow water restriction. Because herbal medi-
cines are generally in granule forms and bitter taste, it
requires a certain amount of drinking water at the time
of medication. They are more difficult to take than a
tablet form; therefore, JDI in capsules or tablets should
be desirable in the future. Because the patient accompan-
ied with shivering and high fever, he was administered JDI
with use of a jelly specialized for Kampo drugs without
drinking water (Rakuraku fukuyaku jelly for Kampo medi-
cine, Ryukakusan, Tokyo, Japan) [14].
JDI can be not only safely used for HD patients with
fewer side-effects but also a cheap medicine from the
viewpoint of medical economics. Traditional Japanese
Kampo and modern medical approaches should be
incorporated into the future medical system to exploit
the advantage of both medicine. A large number of
cases using JDI should be accumulated to maximize the
benefits and confirm the excellent effectiveness of JDI
in the future.Conclusions
The present case indicated as follows: JDI controls the
pain associated with hematoma without analgesics such as
NSAIDs; JDI also has an effect of improving the complica-
tions associated with venous thrombosis and subcutane-
ous hematoma caused by catheterization in HD patients
safely. JDI, one of Kampo drugs, has few side effects and
can be used as needed.
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